Genmab A/S GMAB 深 滬
等待開盤 03-26 09:30:00 美东时间
26.11
+0.300
+1.16%
華盛通- 最 高26.365
- 今 開25.94
- 成交量 315.40万股
- 最 低 25.90
- 昨 收 25.81
- 總市值 167.73亿
- 52周最高 35.43
- 市盈率 靜 16.95
- 換手率 0.49%
- 52周最低 17.235
- 委 比 -90.19%
- 總股本 6.42亿
- 歷史最高 49.07
- 量 比 2.11
- 振 幅 1.80%
- 歷史最低 16.24
- 每 手 1
- 風險率 4.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
<p> BioNTech will present data at the European Lung Cancer Congress highlighting progress in late-stage lung cancer treatments, including bispecific immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. Updates on pumitamig and gotistobart show promising efficacy and safety profiles across various lung cancer subtypes. These advancements underscore BioNTech's commitment to offering transformative treatment options for lung ...
03-24 10:45
Genmab Updates Articles of Association, Expands Capital Issuance Flexibility
The latest update is out from Genmab ( ($GMAB) ). On March 23, 2026, Genmab A/S...
03-23 22:24
Genmab Ends Early‑Stage PRO1160 Cancer Trial: What It Means for GMAB Investors
Genmab (Otc) ($GMAB) announced an update on their ongoing clinical study. Genma...
03-05 00:31
Simulations Plus to Host Responsible AI in MIDD Panel at ASCPT Annual Meeting
Simulations Plus to Host Responsible AI in MIDD Panel at ASCPT Annual Meeting Simulations Plus Inc. said it will hold a panel discussion titled “From Debate to Deployment: Responsible, Practical AI in MIDD” during the ASCPT Annual Meeting on March 5, 2026 at 12:00 PM MST in Denver, Colorado, in room
03-03 20:55
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Genmab Corrects Insider Share Transaction Pricing in March 2 Filings
The latest announcement is out from Genmab ( ($GMAB) ). On March 2, 2026, Genma...
03-03 19:40
Genmab Announces Capital Increase Following Employee Warrant Exercises
Genmab ( ($GMAB) ) has provided an announcement. Genmab A/S, the Copenhagen‑bas...
02-25 04:47
Bolt Biotherapeutics to Participate in Upcoming March Conferences
Bolt Biotherapeutics, a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer, announced its participation in two upcoming conferences in March 2026. On March 2, the company will present at the TD Cowen 46th Annual Health Care Conference, and on March 11, management will engage in 1x1 meetings at the Leerink Partners Global Healthcare Conference. Bolt Biotherapeutics is advancing BDC-4182, a next-generati...
02-24 13:00
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
Guggenheim Maintains Buy on Genmab, Lowers Price Target to $40
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $45 to $40.
02-24 01:00
